Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122342) titled 'Efficacy of standard therapy combined with telitacicept in patients with relapsed IgG4-related disease: a prospective clinical trial' on April 13.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Air Force Medical University of the Chinese People's Liberation Army
Condition:
IgG4-related disease
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-04-13
Target Sample Size: Experimental group:10;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=314443
Published by HT D...